{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:59:42Z","timestamp":1791914382968,"version":"4.3.4"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,6]]},"DOI":"10.7759\/cureus.91728","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:14:12Z","timestamp":1757171652000},"source":"Crossref","is-referenced-by-count":6,"title":["Patterns of Glomerular Injury: Histopathological Classification and Clinical Correlation"],"prefix":"10.7759","author":[{"given":"Hussein","family":"Qasim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abu Shugaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaima'","family":"Dibian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahfouz","family":"Ktaifan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karis","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Luigi Giuseppe","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09400913","article-title":"The glomerulus: the sphere of influence","volume":"9","author":"Pollak MR","year":"2014","unstructured":"Pollak MR, Quaggin SE, Hoenig MP, Dworkin LD. The glomerulus: the sphere of influence. Clin J Am Soc Nephrol. 2014, 9:1461-9. 10.2215\/CJN.09400913","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/749010","article-title":"The glomerular filtration barrier: components and crosstalk","volume":"2012","author":"Menon MC","year":"2012","unstructured":"Menon MC, Chuang PY, He CJ. The glomerular filtration barrier: components and crosstalk. Int J Nephrol. 2012, 2012:749010. 10.1155\/2012\/749010","journal-title":"Int J Nephrol"},{"key":"ref3","article-title":"Glomerular filtration barrier assembly: an insight","volume":"1","author":"Arif E","year":"2013","unstructured":"Arif E, Nihalani D. Glomerular filtration barrier assembly: an insight. Postdoc J. 2013, 1:33-45.","journal-title":"Postdoc J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000452702","article-title":"Intravenous fluids and acute kidney injury","volume":"43","author":"Ding X","year":"2017","unstructured":"Ding X, Cheng Z, Qian Q. Intravenous fluids and acute kidney injury. Blood Purif. 2017, 43:163-72. 10.1159\/000452702","journal-title":"Blood Purif"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00242-0","article-title":"The glomerular filtration barrier: a structural target for novel kidney therapies","volume":"20","author":"Daehn IS","year":"2021","unstructured":"Daehn IS, Duffield JS. The glomerular filtration barrier: a structural target for novel kidney therapies. Nat Rev Drug Discov. 2021, 20:770-88. 10.1038\/s41573-021-00242-0","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.849693","article-title":"Interactions between podocytes, mesangial cells, and glomerular endothelial cells in glomerular diseases","volume":"13","author":"Imig JD","year":"2022","unstructured":"Imig JD, Zhao X, Elmarakby AA, Pavlov T. Interactions between podocytes, mesangial cells, and glomerular endothelial cells in glomerular diseases. Front Physiol. 2022, 13:849693. 10.3389\/fphys.2022.849693","journal-title":"Front Physiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.17.206441","article-title":"The global burden of kidney disease and the sustainable development goals","volume":"96","author":"Luyckx VA","year":"2018","unstructured":"Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018, 96:414-422. 10.2471\/BLT.17.206441","journal-title":"Bull World Health Organ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1042\/CS20210625","article-title":"Mechanisms of podocyte injury and implications for diabetic nephropathy","volume":"136","author":"Barutta F","year":"2022","unstructured":"Barutta F, Bellini S, Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy. Clin Sci (Lond). 2022, 136:493-520. 10.1042\/CS20210625","journal-title":"Clin Sci (Lond)"},{"key":"ref9","article-title":"Clinical presentation and management of glomerular diseases: hematuria, nephritic and nephrotic syndrome","volume":"108","author":"Khanna R","year":"2011","unstructured":"Khanna R. Clinical presentation and management of glomerular diseases: hematuria, nephritic and nephrotic syndrome. Mo Med. 2011, 108:33-6.","journal-title":"Mo Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53923","article-title":"Nephrotic syndrome: a review","volume":"16","author":"Verma PR","year":"2024","unstructured":"Verma PR, Patil P. Nephrotic syndrome: a review. Cureus. 2024, 16:e53923. 10.7759\/cureus.53923","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v14.i2.103756","article-title":"Essential role of kidney biopsy in diagnosing glomerular diseases amidst evolving biomarkers","volume":"14","author":"Gonzalez FM","year":"2025","unstructured":"Gonzalez FM, Valjalo R. Essential role of kidney biopsy in diagnosing glomerular diseases amidst evolving biomarkers. World J Nephrol. 2025, 14:103756. 10.5527\/wjn.v14.i2.103756","journal-title":"World J Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000542497","article-title":"Immunofluorescence use and techniques in glomerular diseases: a review","volume":"4","author":"Messias N","year":"2024","unstructured":"Messias N. Immunofluorescence use and techniques in glomerular diseases: a review. Glomerular Dis. 2024, 4:227-40. 10.1159\/000542497","journal-title":"Glomerular Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151435","article-title":"Glomerular diseases across lifespan: key differences in diagnostic and therapeutic approaches","volume":"43","author":"Windpessl M","year":"2023","unstructured":"Windpessl M, Odler B, Bajema IM, et al.. Glomerular diseases across lifespan: key differences in diagnostic and therapeutic approaches. Semin Nephrol. 2023, 43:151435. 10.1016\/j.semnephrol.2023.151435","journal-title":"Semin Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cells11101625","article-title":"Pathogenic T-cell responses in immune-mediated glomerulonephritis","volume":"11","author":"Linke A","year":"2022","unstructured":"Linke A, Tiegs G, Neumann K. Pathogenic T-cell responses in immune-mediated glomerulonephritis. Cells. 2022, 11:1625. 10.3390\/cells11101625","journal-title":"Cells"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.06.001","article-title":"The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus","volume":"121","author":"Oates JC","year":"2006","unstructured":"Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006, 121:243-50. 10.1016\/j.clim.2006.06.001","journal-title":"Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00816-y","article-title":"Glomerulonephritis: immunopathogenesis and immunotherapy","volume":"23","author":"Anders HJ","year":"2023","unstructured":"Anders HJ, Kitching AR, Leung N, Romagnani P. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat Rev Immunol. 2023, 23:453-71. 10.1038\/s41577-022-00816-y","journal-title":"Nat Rev Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith RJ","year":"2019","unstructured":"Smith RJ, Appel GB, Blom AM, et al.. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019, 15:129-43. 10.1038\/s41581-018-0107-2","journal-title":"Nat Rev Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1335936","article-title":"Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy","volume":"14","author":"Jiang H","year":"2023","unstructured":"Jiang H, Shen Z, Zhuang J, et al.. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy. Front Immunol. 2023, 14:1335936. 10.3389\/fimmu.2023.1335936","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000410","article-title":"The podocyte's response to injury: role in proteinuria and glomerulosclerosis","volume":"69","author":"Shankland SJ","year":"2006","unstructured":"Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006, 69:2131-47. 10.1038\/sj.ki.5000410","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000499","article-title":"Minimal change disease and FSGS are a spectrum of a single disease within immune-mediated nephrotic syndrome","volume":"5","author":"Sim JJ","year":"2024","unstructured":"Sim JJ, Smoyer WE, Schachter AD. Minimal change disease and FSGS are a spectrum of a single disease within immune-mediated nephrotic syndrome. Kidney360. 2024, 5:1197-9. 10.34067\/KID.0000000000000499","journal-title":"Kidney360"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases","volume":"220","author":"Magro C","year":"2020","unstructured":"Magro C, Mulvey JJ, Berlin D, et al.. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020, 220:1-13. 10.1016\/j.trsl.2020.04.007","journal-title":"Transl Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112978","article-title":"Three diseases mediated by different immunopathologic mechanisms\u2014ANCA-associated vasculitis, anti-glomerular basement membrane disease, and immune complex-mediated glomerulonephritis\u2014a common clinical and histopathologic picture: rapidly progressive crescentic glomerulonephritis","volume":"11","author":"Gluhovschi C","year":"2023","unstructured":"Gluhovschi C, Gadalean F, Velciov S, Nistor M, Petrica L. Three diseases mediated by different immunopathologic mechanisms\u2014ANCA-associated vasculitis, anti-glomerular basement membrane disease, and immune complex-mediated glomerulonephritis\u2014a common clinical and histopathologic picture: rapidly progressive crescentic glomerulonephritis. Biomedicines. 2023, 11:2978. 10.3390\/biomedicines11112978","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00205","article-title":"Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood","volume":"8","author":"Mastrangelo A","year":"2020","unstructured":"Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood. Front Pediatr. 2020, 8:205. 10.3389\/fped.2020.00205","journal-title":"Front Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44620","article-title":"Digital pathology: transforming diagnosis in the digital age","volume":"15","author":"Kiran N","year":"2023","unstructured":"Kiran N, Sapna F, Kiran F, et al.. Digital pathology: transforming diagnosis in the digital age. Cureus. 2023, 15:e44620. 10.7759\/cureus.44620","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.03.001","article-title":"Minimal change disease: more than a podocytopathy?","volume":"7","author":"Maas RJ","year":"2022","unstructured":"Maas RJ, Nijenhuis T, van der Vlag J. Minimal change disease: more than a podocytopathy?. Kidney Int Rep. 2022, 7:675-7. 10.1016\/j.ekir.2022.03.001","journal-title":"Kidney Int Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2017.58.281","article-title":"IgM as a novel predictor of disease progression in secondary focal segmental glomerulosclerosis","volume":"58","author":"Pa\u010di\u0107 A","year":"2017","unstructured":"Pa\u010di\u0107 A, \u0160enjug P, Bacalja J, et al.. IgM as a novel predictor of disease progression in secondary focal segmental glomerulosclerosis. Croat Med J. 2017, 58:281-91. 10.3325\/cmj.2017.58.281","journal-title":"Croat Med J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S126844","article-title":"Optimal management of primary focal segmental glomerulosclerosis in adults","volume":"10","author":"Beaudreuil S","year":"2017","unstructured":"Beaudreuil S, Lorenzo HK, Elias M, Nnang Obada E, Charpentier B, Durrbach A. Optimal management of primary focal segmental glomerulosclerosis in adults. Int J Nephrol Renovasc Dis. 2017, 10:97-107. 10.2147\/IJNRD.S126844","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.611317","article-title":"Secondary membranous nephropathy: a narrative review","volume":"7","author":"Moroni G","year":"2020","unstructured":"Moroni G, Ponticelli C. Secondary membranous nephropathy: a narrative review. Front Med (Lausanne). 2020, 7:611317. 10.3389\/fmed.2020.611317","journal-title":"Front Med (Lausanne)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.399","article-title":"Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion","volume":"81","author":"Sethi S","year":"2012","unstructured":"Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012, 81:434-41. 10.1038\/ki.2011.399","journal-title":"Kidney Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000520640","article-title":"KM55 in the evaluation of IgA-containing glomerular diseases","volume":"2","author":"Raj R","year":"2022","unstructured":"Raj R, Sharma A, Barwad A, et al.. KM55 in the evaluation of IgA-containing glomerular diseases. Glomerular Dis. 2022, 2:59-74. 10.1159\/000520640","journal-title":"Glomerular Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/402826","article-title":"Pauci-immune crescentic glomerulonephritis: an ANCA-associated vasculitis","volume":"2015","author":"Syed R","year":"2015","unstructured":"Syed R, Rehman A, Valecha G, El-Sayegh S. Pauci-immune crescentic glomerulonephritis: an ANCA-associated vasculitis. Biomed Res Int. 2015, 2015:402826. 10.1155\/2015\/402826","journal-title":"Biomed Res Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.09.028","article-title":"Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age\u00a0adjustment","volume":"93","author":"Hommos MS","year":"2018","unstructured":"Hommos MS, Zeng C, Liu Z, et al.. Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age\u00a0adjustment. Kidney Int. 2018, 93:1175-82. 10.1016\/j.kint.2017.09.028","journal-title":"Kidney Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.035592","article-title":"Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update","volume":"60","author":"Alsaad KO","year":"2007","unstructured":"Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 2007, 60:18-26. 10.1136\/jcp.2005.035592","journal-title":"J Clin Pathol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.15","article-title":"Chapter 2: general principles in the management of glomerular disease","volume":"2","author":"Kidney International Supplements","year":"2012","unstructured":"Kidney International Supplements. Chapter 2: general principles in the management of glomerular disease. Kidney Int Suppl (2011). 2012, 2:156-62. 10.1038\/kisup.2012.15","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2024.03.005","article-title":"Membranoproliferative glomerulonephritis pattern of injury","volume":"31","author":"Yu SM","year":"2024","unstructured":"Yu SM, Deoliveira M, Chung M, Lafayette R. Membranoproliferative glomerulonephritis pattern of injury. Adv Kidney Dis Health. 2024, 31:216-22. 10.1053\/j.akdh.2024.03.005","journal-title":"Adv Kidney Dis Health"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100151","article-title":"Rational development and application of biomarkers in the field of autoimmunity: a conceptual framework guiding clinicians and researchers","volume":"5","author":"Kolev M","year":"2022","unstructured":"Kolev M, Horn MP, Semmo N, Nagler M. Rational development and application of biomarkers in the field of autoimmunity: a conceptual framework guiding clinicians and researchers. J Transl Autoimmun. 2022, 5:100151. 10.1016\/j.jtauto.2022.100151","journal-title":"J Transl Autoimmun"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012101017","article-title":"Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study","volume":"24","author":"Lv J","year":"2013","unstructured":"Lv J, Yang Y, Zhang H, et al.. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013, 24:2118-25. 10.1681\/ASN.2012101017","journal-title":"J Am Soc Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20024","article-title":"Primary glomerular diseases and long-term adverse health outcomes: a nationwide cohort study","volume":"297","author":"Faucon AL","year":"2025","unstructured":"Faucon AL, Lando S, Chrysostomou C, et al.. Primary glomerular diseases and long-term adverse health outcomes: a nationwide cohort study. J Intern Med. 2025, 297:22-35. 10.1111\/joim.20024","journal-title":"J Intern Med"},{"key":"ref39","doi-asserted-by":"crossref","DOI":"10.1016\/j.mpmed.2019.07.005","article-title":"Secondary glomerular disease","volume":"47","author":"Dattani R","year":"2019","unstructured":"Dattani R, McAdoo S. Secondary glomerular disease. Medicine. 2019, 47:644-8.","journal-title":"Medicine"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14111135","article-title":"Autoimmune diseases and plasma cells dyscrasias: pathogenetic, molecular and prognostic correlations","volume":"14","author":"Giordano L","year":"2024","unstructured":"Giordano L, Cacciola R, Barone P, et al.. Autoimmune diseases and plasma cells dyscrasias: pathogenetic, molecular and prognostic correlations. Diagnostics (Basel). 2024, 14:1135. 10.3390\/diagnostics14111135","journal-title":"Diagnostics (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening JJ","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, et al.. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004, 65:521-30. 10.1111\/j.1523-1755.2004.00443.x","journal-title":"Kidney Int"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/132085","article-title":"Crescentic glomerulonephritis with anti-GBM and p-ANCA antibodies","volume":"2012","author":"Javed T","year":"2012","unstructured":"Javed T, Vohra P. Crescentic glomerulonephritis with anti-GBM and p-ANCA antibodies. Case Rep Nephrol. 2012, 2012:132085. 10.1155\/2012\/132085","journal-title":"Case Rep Nephrol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1159\/000516790","article-title":"Lupus nephritis: the significant contribution of electron microscopy","volume":"1","author":"Truong L","year":"2021","unstructured":"Truong L, Seshan SV. Lupus nephritis: the significant contribution of electron microscopy. Glomerular Dis. 2021, 1:180-204. 10.1159\/000516790","journal-title":"Glomerular Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2024.04.007","article-title":"Anti-glomerular basement membrane disease: recent updates","volume":"31","author":"Bharati J","year":"2024","unstructured":"Bharati J, Jhaveri KD, Salama AD, Oni L. Anti-glomerular basement membrane disease: recent updates. Adv Kidney Dis Health. 2024, 31:206-15. 10.1053\/j.akdh.2024.04.007","journal-title":"Adv Kidney Dis Health"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05911-9","article-title":"Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies","volume":"104","author":"Cassano Cassano R","year":"2025","unstructured":"Cassano Cassano R, Bonadio AG, Del Giudice ML, Giannese D, Galimberti S, Buda G. Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies. Ann Hematol. 2025, 104:2083-93. 10.1007\/s00277-024-05911-9","journal-title":"Ann Hematol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015060612","article-title":"Mayo Clinic\/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN","volume":"27","author":"Sethi S","year":"2016","unstructured":"Sethi S, Haas M, Markowitz GS, et al.. Mayo Clinic\/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016, 27:1278-87. 10.1681\/ASN.2015060612","journal-title":"J Am Soc Nephrol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.4103\/JMAU.JMAU_8_20","article-title":"Crescents in kidney biopsy - what do they imply? A clinicopathologic study of 40 cases in a tertiary care center","volume":"9","author":"Chauhan S","year":"2021","unstructured":"Chauhan S, Jain S, Garg N, Dixit S, Sharma S. Crescents in kidney biopsy - what do they imply? A clinicopathologic study of 40 cases in a tertiary care center. J Microsc Ultrastruct. 2021, 9:81-5. 10.4103\/JMAU.JMAU_8_20","journal-title":"J Microsc Ultrastruct"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.1.25","article-title":"The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome","volume":"161","author":"Madaio MP","year":"2001","unstructured":"Madaio MP, Harrington JT. The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med. 2001, 161:25-34. 10.1001\/archinte.161.1.25","journal-title":"Arch Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014030267","article-title":"Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics","volume":"25","author":"Mac\u00e9 C","year":"2014","unstructured":"Mac\u00e9 C, Chugh SS. Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. J Am Soc Nephrol. 2014, 25:2393-8. 10.1681\/ASN.2014030267","journal-title":"J Am Soc Nephrol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1159\/000354390","article-title":"Differential diagnosis of glomerular disease: a systematic and inclusive approach","volume":"38","author":"Hebert LA","year":"2013","unstructured":"Hebert LA, Parikh S, Prosek J, Nadasdy T, Rovin BH. Differential diagnosis of glomerular disease: a systematic and inclusive approach. Am J Nephrol. 2013, 38:253-66. 10.1159\/000354390","journal-title":"Am J Nephrol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7198.1610","article-title":"Towards an understanding of oedema","volume":"318","author":"Diskin CJ","year":"1999","unstructured":"Diskin CJ, Stokes TJ, Dansby LM, Carter TB, Radcliff L, Thomas SG. Towards an understanding of oedema. BMJ. 1999, 318:1610-3. 10.1136\/bmj.318.7198.1610","journal-title":"BMJ"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102162","article-title":"Thromboembolism in nephrotic syndrome: controversies and uncertainties","volume":"7","author":"Parker K","year":"2023","unstructured":"Parker K, Ragy O, Hamilton P, Thachil J, Kanigicherla D. Thromboembolism in nephrotic syndrome: controversies and uncertainties. Res Pract Thromb Haemost. 2023, 7:102162. 10.1016\/j.rpth.2023.102162","journal-title":"Res Pract Thromb Haemost"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05746-4","article-title":"How to define and assess the clinically significant causes of hematuria in childhood","volume":"38","author":"Horv\u00e1th O","year":"2023","unstructured":"Horv\u00e1th O, Szab\u00f3 AJ, Reusz GS. How to define and assess the clinically significant causes of hematuria in childhood. Pediatr Nephrol. 2023, 38:2549-62. 10.1007\/s00467-022-05746-4","journal-title":"Pediatr Nephrol"},{"key":"ref54","article-title":"Poststreptococcal glomerulonephritis","author":"Rawla P","year":"2025","unstructured":"Rawla P, Padala SA, Ludhwani D. Poststreptococcal glomerulonephritis. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref55","article-title":"Nephritic syndrome","author":"Hashmi MS","year":"2023","unstructured":"Hashmi MS, Pandey J. Nephritic syndrome. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.02.022","article-title":"Glomerular hematuria and the utility of urine microscopy: a review","volume":"80","author":"Saha MK","year":"2022","unstructured":"Saha MK, Massicotte-Azarniouch D, Reynolds ML, Mottl AK, Falk RJ, Jennette JC, Derebail VK. Glomerular hematuria and the utility of urine microscopy: a review. Am J Kidney Dis. 2022, 80:383-92. 10.1053\/j.ajkd.2022.02.022","journal-title":"Am J Kidney Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000596","article-title":"The glomerular crescent: triggers, evolution, resolution, and implications for therapy","volume":"29","author":"Anguiano L","year":"2020","unstructured":"Anguiano L, Kain R, Anders HJ. The glomerular crescent: triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens. 2020, 29:302-9. 10.1097\/MNH.0000000000000596","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73233","article-title":"An insidious case of rapidly progressive glomerulonephritis secondary to pauci-immune crescentic glomerulonephritis","volume":"16","author":"Mavratsas VC","year":"2024","unstructured":"Mavratsas VC, Vu L, Yeh OL. An insidious case of rapidly progressive glomerulonephritis secondary to pauci-immune crescentic glomerulonephritis. Cureus. 2024, 16:e73233. 10.7759\/cureus.73233","journal-title":"Cureus"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04820511","article-title":"Clinical features and outcomes of IgA nephropathy with nephrotic syndrome","volume":"7","author":"Kim JK","year":"2012","unstructured":"Kim JK, Kim JH, Lee SC, et al.. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol. 2012, 7:427-36. 10.2215\/CJN.04820511","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0003222020","article-title":"Approach to persistent microscopic hematuria in children","volume":"1","author":"Kallash M","year":"2020","unstructured":"Kallash M, Rheault MN. Approach to persistent microscopic hematuria in children. Kidney360. 2020, 1:1014-20. 10.34067\/KID.0003222020","journal-title":"Kidney360"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-4617-0.00016-9","article-title":"16 - Glomerular clinicopathologic syndromes","author":"Jennette JC","unstructured":"Jennette JC, Falk RJ. 16 - Glomerular clinicopathologic syndromes. National Kidney Foundation Primer on Kidney Diseases (Sixth Edition). Gilbert SJ, Weiner DE (ed): WB Saunders, Philadelphia, PA; 10.1016\/B978-1-4557-4617-0.00016-9"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.127892","article-title":"Changing histologic spectrum of adult nephrotic syndrome over five decades in north India: a single center experience","volume":"24","author":"Rathi M","year":"2014","unstructured":"Rathi M, Bhagat RL, Mukhopadhyay P, et al.. Changing histologic spectrum of adult nephrotic syndrome over five decades in north India: a single center experience. Indian J Nephrol. 2014, 24:86-91. 10.4103\/0971-4065.127892","journal-title":"Indian J Nephrol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: an interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran A","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021, 361:176-94. 10.1016\/j.amjms.2020.10.003","journal-title":"Am J Med Sci"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-47794-9.00022-6","article-title":"Infection-related glomerulonephritis","author":"Provenzano LF","year":"2018","unstructured":"Provenzano LF, Herlitz L. Infection-related glomerulonephritis. National Kidney Foundation's Primer on Kidney Diseases. Gilbert SJ, Weiner DE (ed): Elsevier, Philadelphia, PA; 2018. 10.1016\/B978-0-323-47794-9.00022-6"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436923","article-title":"Contemporary review of IgA nephropathy","volume":"15","author":"Filippone EJ","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol. 2024, 15:1436923. 10.3389\/fimmu.2024.1436923","journal-title":"Front Immunol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-023-00809-3","article-title":"Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy","volume":"13","author":"Oba Y","year":"2024","unstructured":"Oba Y, Mizuno H, Taneda S, et al.. Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy. CEN Case Rep. 2024, 13:110-6. 10.1007\/s13730-023-00809-3","journal-title":"CEN Case Rep"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-022-00313-8","article-title":"Presentation of SLE after COVID vaccination in a pediatric patient","volume":"6","author":"Nelson MC","year":"2022","unstructured":"Nelson MC, Rytting H, Greenbaum LA, Goldberg B. Presentation of SLE after COVID vaccination in a pediatric patient. BMC Rheumatol. 2022, 6:81. 10.1186\/s41927-022-00313-8","journal-title":"BMC Rheumatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1227-z","article-title":"A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis","volume":"20","author":"Sporinova B","year":"2019","unstructured":"Sporinova B, McRae SA, Muruve DA, Fritzler MJ, Nasr SH, Chin AC, Benediktsson H. A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis. BMC Nephrol. 2019, 20:29. 10.1186\/s12882-019-1227-z","journal-title":"BMC Nephrol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2015.12.87","article-title":"Diabetic kidney disease: a syndrome rather than a single disease","volume":"12","author":"Piccoli GB","year":"2015","unstructured":"Piccoli GB, Grassi G, Cabiddu G, et al.. Diabetic kidney disease: a syndrome rather than a single disease. Rev Diabet Stud. 2015, 12:87-109. 10.1900\/RDS.2015.12.87","journal-title":"Rev Diabet Stud"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196424","article-title":"Renal biopsy for diagnosis in kidney disease: indication, technique, and safety","volume":"12","author":"Schnuelle P","year":"2023","unstructured":"Schnuelle P. Renal biopsy for diagnosis in kidney disease: indication, technique, and safety. J Clin Med. 2023, 12:96424. 10.3390\/jcm12196424","journal-title":"J Clin Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.4103\/JMAU.JMAU_62_20","article-title":"Role of direct immunofluorescence microscopy in spectrum of diffuse proliferative glomerulonephritis: a single-center study","volume":"9","author":"Jain S","year":"2021","unstructured":"Jain S, Chauhan S, Dixit S, Garg N, Sharma S. Role of direct immunofluorescence microscopy in spectrum of diffuse proliferative glomerulonephritis: a single-center study. J Microsc Ultrastruct. 2021, 9:177-82. 10.4103\/JMAU.JMAU_62_20","journal-title":"J Microsc Ultrastruct"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.114462","article-title":"Basics of kidney biopsy: a nephrologist's perspective","volume":"23","author":"Agarwal SK","year":"2013","unstructured":"Agarwal SK, Sethi S, Dinda AK. Basics of kidney biopsy: a nephrologist's perspective. Indian J Nephrol. 2013, 23:243-52. 10.4103\/0971-4065.114462","journal-title":"Indian J Nephrol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v13.i7.498","article-title":"Biochemical composition of the glomerular extracellular matrix in patients with diabetic kidney disease","volume":"13","author":"Adeva-Andany MM","year":"2022","unstructured":"Adeva-Andany MM, Carneiro-Freire N. Biochemical composition of the glomerular extracellular matrix in patients with diabetic kidney disease. World J Diabetes. 2022, 13:498-520. 10.4239\/wjd.v13.i7.498","journal-title":"World J Diabetes"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1992-9","article-title":"Tubulointerstitial injury and the progression of chronic kidney disease","volume":"27","author":"Hodgkins KS","year":"2012","unstructured":"Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol. 2012, 27:901-9. 10.1007\/s00467-011-1992-9","journal-title":"Pediatr Nephrol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318776907","article-title":"Immunohistochemistry in investigative and toxicologic pathology","volume":"46","author":"Janardhan KS","year":"2018","unstructured":"Janardhan KS, Jensen H, Clayton NP, Herbert RA. Immunohistochemistry in investigative and toxicologic pathology. Toxicol Pathol. 2018, 46:488-510. 10.1177\/0192623318776907","journal-title":"Toxicol Pathol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a\u00a0decade after its discovery","volume":"96","author":"van de Logt AE","year":"2019","unstructured":"van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a\u00a0decade after its discovery. Kidney Int. 2019, 96:1292-302. 10.1016\/j.kint.2019.07.014","journal-title":"Kidney Int"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.08.006","article-title":"Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society","volume":"98","author":"Haas M","year":"2020","unstructured":"Haas M, Seshan SV, Barisoni L, et al.. Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society. Kidney Int. 2020, 98:1120-34. 10.1016\/j.kint.2020.08.006","journal-title":"Kidney Int"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1354698","article-title":"Diagnostic and treatment workup for IgG4-related disease","volume":"13","author":"Abraham M","year":"2017","unstructured":"Abraham M, Khosroshahi A. Diagnostic and treatment workup for IgG4-related disease. Expert Rev Clin Immunol. 2017, 13:867-75. 10.1080\/1744666X.2017.1354698","journal-title":"Expert Rev Clin Immunol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181415","article-title":"Congo Red and amyloids: history and relationship","volume":"39","author":"Yakupova EI","year":"2019","unstructured":"Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo Red and amyloids: history and relationship. Biosci Rep. 2019, 39:BSR20181415. 10.1042\/BSR20181415","journal-title":"Biosci Rep"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000221","article-title":"From patterns to proteins: mass spectrometry comes of age in glomerular disease","volume":"35","author":"Sethi S","year":"2024","unstructured":"Sethi S, Theis JD, Palma LM, Madden B. From patterns to proteins: mass spectrometry comes of age in glomerular disease. J Am Soc Nephrol. 2024, 35:117-28. 10.1681\/ASN.0000000000000221","journal-title":"J Am Soc Nephrol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062450","article-title":"The spectrum of minimal change disease\/focal segmental glomerulosclerosis: from pathogenesis to proteomic biomarker research","volume":"26","author":"Maslyennikov Y","year":"2025","unstructured":"Maslyennikov Y, B\u0103rar AA, Rusu CC, et al.. The spectrum of minimal change disease\/focal segmental glomerulosclerosis: from pathogenesis to proteomic biomarker research. Int J Mol Sci. 2025, 26:2450. 10.3390\/ijms26062450","journal-title":"Int J Mol Sci"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212174","article-title":"Detailed pathophysiology of minimal change disease: insights into podocyte dysfunction, immune dysregulation, and genetic susceptibility","volume":"25","author":"Roman M","year":"2024","unstructured":"Roman M, Nowicki M. Detailed pathophysiology of minimal change disease: insights into podocyte dysfunction, immune dysregulation, and genetic susceptibility. Int J Mol Sci. 2024, 25:12174. 10.3390\/ijms252212174","journal-title":"Int J Mol Sci"},{"key":"ref83","article-title":"Effects of podocyte foot process effacement on kidney prognosis and response to immunosuppressive therapy in IgA nephropathy","volume":"7","author":"Guo Y","year":"2025","unstructured":"Guo Y, Ren Y, Shi S, et al.. Effects of podocyte foot process effacement on kidney prognosis and response to immunosuppressive therapy in IgA nephropathy. Kidney Med. 2025, 7:101049.","journal-title":"Kidney Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4632768","article-title":"FSGS: diagnosis and diagnostic work-up","volume":"2016","author":"Sprangers B","year":"2016","unstructured":"Sprangers B, Meijers B, Appel G. FSGS: diagnosis and diagnostic work-up. Biomed Res Int. 2016, 2016:4632768. 10.1155\/2016\/4632768","journal-title":"Biomed Res Int"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg AZ","year":"2017","unstructured":"Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017, 12:502-17. 10.2215\/CJN.05960616","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2014.05.010","article-title":"Permeability factors in focal and segmental glomerulosclerosis","volume":"21","author":"Reiser J","year":"2014","unstructured":"Reiser J, Nast CC, Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014, 21:417-21. 10.1053\/j.ackd.2014.05.010","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12045","article-title":"Recent progress in the pathophysiology and treatment of FSGS recurrence","volume":"13","author":"Cravedi P","year":"2013","unstructured":"Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant. 2013, 13:266-74. 10.1111\/ajt.12045","journal-title":"Am J Transplant"},{"key":"ref88","article-title":"Focal segmental glomerulosclerosis","author":"Rout P","year":"2024","unstructured":"Rout P, Hashmi MF, Baradhi KM. Focal segmental glomerulosclerosis. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref89","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100501","article-title":"Efficacy and safety of immunosuppressive therapy in primary focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"4","author":"Caster DJ","year":"2022","unstructured":"Caster DJ, Magalhaes B, Pennese N, et al.. Efficacy and safety of immunosuppressive therapy in primary focal segmental glomerulosclerosis: a systematic review and meta-analysis. Kidney Med. 2022, 4:100501.","journal-title":"Kidney Med"},{"key":"ref90","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100826","article-title":"A review of focal segmental glomerulosclerosis classification with a focus on genetic associations","volume":"6","author":"Bonilla M","year":"2024","unstructured":"Bonilla M, Efe O, Selvaskandan H, Lerma EV, Wiegley N. A review of focal segmental glomerulosclerosis classification with a focus on genetic associations. Kidney Med. 2024, 6:100826.","journal-title":"Kidney Med"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa110","article-title":"Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers","volume":"14","author":"Jacobs-Cach\u00e1 C","year":"2021","unstructured":"Jacobs-Cach\u00e1 C, Vergara A, Garc\u00eda-Carro C, et al.. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. Clin Kidney J. 2021, 14:482-91. 10.1093\/ckj\/sfaa110","journal-title":"Clin Kidney J"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16242","article-title":"NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele","volume":"110","author":"Tsukaguchi H","year":"2002","unstructured":"Tsukaguchi H, Sudhakar A, Le TC, et al.. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. 2002, 110:1659-66. 10.1172\/JCI16242","journal-title":"J Clin Invest"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0615-5","article-title":"Membranous nephropathy: a retrospective observational study of membranous nephropathy in north east and central London","volume":"18","author":"Gupta S","year":"2017","unstructured":"Gupta S, Connolly J, Pepper RJ, Walsh SB, Yaqoob MM, Kleta R, Ashman N. Membranous nephropathy: a retrospective observational study of membranous nephropathy in north east and central London. BMC Nephrol. 2017, 18:201. 10.1186\/s12882-017-0615-5","journal-title":"BMC Nephrol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v11.i4.115","article-title":"New antigens involved in membranous nephropathy beyond phospholipase A2 receptor","volume":"11","author":"Salvadori M","year":"2022","unstructured":"Salvadori M, Tsalouchos A. New antigens involved in membranous nephropathy beyond phospholipase A2 receptor. World J Nephrol. 2022, 11:115-26. 10.5527\/wjn.v11.i4.115","journal-title":"World J Nephrol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S176665","article-title":"Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults","volume":"11","author":"Wu X","year":"2018","unstructured":"Wu X, Liu L, Guo Y, Yang L. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults. Int J Nephrol Renovasc Dis. 2018, 11:241-7. 10.2147\/IJNRD.S176665","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1159\/000529700","article-title":"Characterization of membranous nephropathy with microspherular deposits","volume":"3","author":"Ren KY","year":"2023","unstructured":"Ren KY, Hou J. Characterization of membranous nephropathy with microspherular deposits. Glomerular Dis. 2023, 3:197-210. 10.1159\/000529700","journal-title":"Glomerular Dis"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.270273","article-title":"Membranous nephropathy in a child with crescentic glomerulonephritis: coincidence or comorbidity?","volume":"30","author":"Girisgen I","year":"2019","unstructured":"Girisgen I, Conkar S, Bulut \u0130K, \u015een S, Mir S. Membranous nephropathy in a child with crescentic glomerulonephritis: coincidence or comorbidity?. Saudi J Kidney Dis Transpl. 2019, 30:1156-60. 10.4103\/1319-2442.270273","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw227","article-title":"Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome","volume":"32","author":"Gyamlani G","year":"2017","unstructured":"Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017, 32:157-64. 10.1093\/ndt\/gfw227","journal-title":"Nephrol Dial Transplant"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092880","article-title":"Prognostic factors of proteinuria remission in primary membranous nephropathy","volume":"14","author":"Krakowska-Jura K","year":"2025","unstructured":"Krakowska-Jura K, Kler AN, Wajerowska W, Konieczny A, Banasik M. Prognostic factors of proteinuria remission in primary membranous nephropathy. J Clin Med. 2025, 14:2880. 10.3390\/jcm14092880","journal-title":"J Clin Med"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad075","article-title":"Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy","volume":"16","author":"Zand L","year":"2023","unstructured":"Zand L, Fervenza FC. Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy. Clin Kidney J. 2023, 16:1420-5. 10.1093\/ckj\/sfad075","journal-title":"Clin Kidney J"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03555-5","article-title":"Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries","volume":"25","author":"Zaidi O","year":"2024","unstructured":"Zaidi O, Du F, Tang Z, Bhattacharjee S, Pareja K. Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries. BMC Nephrol. 2024, 25:136. 10.1186\/s12882-024-03555-5","journal-title":"BMC Nephrol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac204","article-title":"Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries","volume":"37","author":"Makita Y","year":"2022","unstructured":"Makita Y, Suzuki H, Nakano D, et al.. Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries. Nephrol Dial Transplant. 2022, 37:1629-36. 10.1093\/ndt\/gfac204","journal-title":"Nephrol Dial Transplant"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00840.x","article-title":"Pathophysiology of proteinuria","volume":"63","author":"D'Amico G","year":"2003","unstructured":"D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003, 63:809-25. 10.1046\/j.1523-1755.2003.00840.x","journal-title":"Kidney Int"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02653-y","article-title":"Utilizing the MEST score for prognostic staging in IgA nephropathy","volume":"23","author":"Haaskjold YL","year":"2022","unstructured":"Haaskjold YL, Bj\u00f8rneklett R, Bostad L, Bostad LS, Lura NG, Knoop T. Utilizing the MEST score for prognostic staging in IgA nephropathy. BMC Nephrol. 2022, 23:26. 10.1186\/s12882-021-02653-y","journal-title":"BMC Nephrol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh139","article-title":"Distinguishing C1q nephropathy from lupus nephritis","volume":"19","author":"Sharman A","year":"2004","unstructured":"Sharman A, Furness P, Feehally J. Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant. 2004, 19:1420-6. 10.1093\/ndt\/gfh139","journal-title":"Nephrol Dial Transplant"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.02.030","article-title":"Secondary IgA nephropathy","volume":"94","author":"Saha MK","year":"2018","unstructured":"Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018, 94:674-81. 10.1016\/j.kint.2018.02.030","journal-title":"Kidney Int"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1097\/j.pbj.0000000000000264","article-title":"Emerging perspectives in the management of IgA nephropathy: a comprehensive review","volume":"9","author":"Gomes AM","year":"2024","unstructured":"Gomes AM, Schau B, Farinha A. Emerging perspectives in the management of IgA nephropathy: a comprehensive review. Porto Biomed J. 2024, 9:264. 10.1097\/j.pbj.0000000000000264","journal-title":"Porto Biomed J"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama T","year":"2014","unstructured":"Moriyama T, Tanaka K, Iwasaki C, et al.. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014, 9:e91756. 10.1371\/journal.pone.0091756","journal-title":"PLoS One"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud L","year":"2020","unstructured":"Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020, 59:v29-38. 10.1093\/rheumatology\/keaa382","journal-title":"Rheumatology (Oxford)"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2018.06.003","article-title":"Nonproliferative forms of lupus nephritis: an overview","volume":"44","author":"Bomback AS","year":"2018","unstructured":"Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018, 44:561-9. 10.1016\/j.rdc.2018.06.003","journal-title":"Rheum Dis Clin North Am"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.4103\/2231-0770.102278","article-title":"Membranous nephropathy: treatment outline and risk stratification","volume":"2","author":"Arabi Z","year":"2012","unstructured":"Arabi Z. Membranous nephropathy: treatment outline and risk stratification. Avicenna J Med. 2012, 2:60-4. 10.4103\/2231-0770.102278","journal-title":"Avicenna J Med"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01910213","article-title":"Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis","volume":"8","author":"Olson SW","year":"2013","unstructured":"Olson SW, Lee JJ, Prince LK, Baker TP, Papadopoulos P, Edison J, Abbott KC. Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin J Am Soc Nephrol. 2013, 8:1702-8. 10.2215\/CJN.01910213","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1159\/000517259","article-title":"Recurrent glomerular diseases in renal transplantation with focus on role of electron microscopy","volume":"1","author":"Seshan SV","year":"2021","unstructured":"Seshan SV, Salvatore SP. Recurrent glomerular diseases in renal transplantation with focus on role of electron microscopy. Glomerular Dis. 2021, 1:205-36. 10.1159\/000517259","journal-title":"Glomerular Dis"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa381","article-title":"Lupus nephritis: clinical presentations and outcomes in the 21st century","volume":"59","author":"Gasparotto M","year":"2020","unstructured":"Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020, 59:v39-51. 10.1093\/rheumatology\/keaa381","journal-title":"Rheumatology (Oxford)"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.11.023","article-title":"Lupus nephritis: the evolving role of novel therapeutics","volume":"63","author":"Rovin BH","year":"2014","unstructured":"Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis. 2014, 63:677-90. 10.1053\/j.ajkd.2013.11.023","journal-title":"Am J Kidney Dis"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan A","year":"2020","unstructured":"Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, Bass D. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020, 29:1011-20. 10.1177\/0961203320932219","journal-title":"Lupus"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v11.i5.139","article-title":"Management and outcomes of acute post-streptococcal glomerulonephritis in children","volume":"11","author":"Ong LT","year":"2022","unstructured":"Ong LT. Management and outcomes of acute post-streptococcal glomerulonephritis in children. World J Nephrol. 2022, 11:139-45. 10.5527\/wjn.v11.i5.139","journal-title":"World J Nephrol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv119","article-title":"Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?","volume":"9","author":"Kakajiwala A","year":"2016","unstructured":"Kakajiwala A, Bhatti T, Kaplan BS, Ruebner RL, Copelovitch L. Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?. Clin Kidney J. 2016, 9:90-6. 10.1093\/ckj\/sfv119","journal-title":"Clin Kidney J"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20212","article-title":"A comprehensive review study on glomerulonephritis associated with post-streptococcal infection","volume":"13","author":"Alhamoud MA","year":"2021","unstructured":"Alhamoud MA, Salloot IZ, Mohiuddin SS, et al.. A comprehensive review study on glomerulonephritis associated with post-streptococcal infection. Cureus. 2021, 13:e20212. 10.7759\/cureus.20212","journal-title":"Cureus"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.10.018","article-title":"Atypical infection-related glomerulonephritis with \u201cmasked\u201d IgG-kappa crystalline hump-like deposits","volume":"6","author":"DiFranza LT","year":"2021","unstructured":"DiFranza LT, Markowitz GS, D'Agati VD, Santoriello D. Atypical infection-related glomerulonephritis with \u201cmasked\u201d IgG-kappa crystalline hump-like deposits. Kidney Int Rep. 2021, 6:228-33. 10.1016\/j.ekir.2020.10.018","journal-title":"Kidney Int Rep"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137482","article-title":"Staphylococcus aureus infection-related glomerulonephritis with dominant IgA deposition","volume":"23","author":"Takayasu M","year":"2022","unstructured":"Takayasu M, Hirayama K, Shimohata H, Kobayashi M, Koyama A. Staphylococcus aureus infection-related glomerulonephritis with dominant IgA deposition. Int J Mol Sci. 2022, 23:7482. 10.3390\/ijms23137482","journal-title":"Int J Mol Sci"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S40172","article-title":"Diabetic nephropathy - complications and treatment","volume":"7","author":"Lim AKh","year":"2014","unstructured":"Lim AKh. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014, 7:361-81. 10.2147\/IJNRD.S40172","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9570616","article-title":"Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes","volume":"2019","author":"Yang P","year":"2019","unstructured":"Yang P, Feng J, Peng Q, Liu X, Fan Z. Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes. Oxid Med Cell Longev. 2019, 2019:9570616. 10.1155\/2019\/9570616","journal-title":"Oxid Med Cell Longev"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2004.02524.x","article-title":"Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor","volume":"6","author":"Weir MR","year":"2004","unstructured":"Weir MR. Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. J Clin Hypertens (Greenwich). 2004, 6:134-41. 10.1111\/j.1524-6175.2004.02524.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref125","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018, 34:575-84.","journal-title":"Can J Cardiol"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8637138","article-title":"Classification and differential diagnosis of diabetic nephropathy","volume":"2017","author":"Qi C","year":"2017","unstructured":"Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017, 2017:8637138. 10.1155\/2017\/8637138","journal-title":"J Diabetes Res"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1002\/art.38702","article-title":"Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?","volume":"66","author":"Herzog EL","year":"2014","unstructured":"Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. Arthritis Rheumatol. 2014, 66:1967-78. 10.1002\/art.38702","journal-title":"Arthritis Rheumatol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00020.2017","article-title":"Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy","volume":"312","author":"Kriz W","year":"2017","unstructured":"Kriz W, L\u00f6wen J, Federico G, van den Born J, Gr\u00f6ne E, Gr\u00f6ne HJ. Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy. Am J Physiol Renal Physiol. 2017, 312:F1101-11. 10.1152\/ajprenal.00020.2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.22.123","article-title":"Pathological validation of the Japanese Renal Pathology Society classification and challenges in predicting renal prognosis in patients with diabetic nephropathy","volume":"41","author":"Kim T","year":"2022","unstructured":"Kim T, Kwak Y, Lee JY, Shin H, Kim JS, Yang JW, Eom M. Pathological validation of the Japanese Renal Pathology Society classification and challenges in predicting renal prognosis in patients with diabetic nephropathy. Kidney Res Clin Pract. 2022, 41:545-55. 10.23876\/j.krcp.22.123","journal-title":"Kidney Res Clin Pract"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45615","article-title":"The bidirectional link between diabetes and kidney disease: mechanisms and management","volume":"15","author":"Kumar M","year":"2023","unstructured":"Kumar M, Dev S, Khalid MU, et al.. The bidirectional link between diabetes and kidney disease: mechanisms and management. Cureus. 2023, 15:e45615. 10.7759\/cureus.45615","journal-title":"Cureus"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1159\/000543685","article-title":"Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease and beyond","volume":"5","author":"Hannouneh ZA","year":"2025","unstructured":"Hannouneh ZA, Cervantes CE, Hanouneh M, Atta MG. Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease and beyond. Glomerular Dis. 2025, 5:119-32. 10.1159\/000543685","journal-title":"Glomerular Dis"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.03.050","article-title":"Update on acute tubulointerstitial nephritis: clinical features, immunologic insights, and diagnostic and treatment approaches","volume":"10","author":"Sahutoglu T","year":"2025","unstructured":"Sahutoglu T, Perazella MA. Update on acute tubulointerstitial nephritis: clinical features, immunologic insights, and diagnostic and treatment approaches. Kidney Int Rep. 2025, 10:1643-56. 10.1016\/j.ekir.2025.03.050","journal-title":"Kidney Int Rep"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.375","article-title":"Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification","volume":"85","author":"Haas M","year":"2014","unstructured":"Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int. 2014, 85:779-93. 10.1038\/ki.2013.375","journal-title":"Kidney Int"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011030229","article-title":"Urinary FSP1 is a biomarker of crescentic GN","volume":"23","author":"Iwano M","year":"2012","unstructured":"Iwano M, Yamaguchi Y, Iwamoto T, et al.. Urinary FSP1 is a biomarker of crescentic GN. J Am Soc Nephrol. 2012, 23:209-14. 10.1681\/ASN.2011030229","journal-title":"J Am Soc Nephrol"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2226257","article-title":"Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation","volume":"45","author":"Di D","year":"2023","unstructured":"Di D, Liu L, Wang Y, Yang Y, Jiang S, Li W. Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation. Ren Fail. 2023, 45:2226257. 10.1080\/0886022X.2023.2226257","journal-title":"Ren Fail"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11019","article-title":"Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies","volume":"31","author":"Nogueira A","year":"2017","unstructured":"Nogueira A, Pires MJ, Oliveira PA. Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In Vivo. 2017, 31:1-22. 10.21873\/invivo.11019","journal-title":"In Vivo"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20950","article-title":"The shifting landscape of lupus nephritis management: a review","volume":"14","author":"Bankole AA","year":"2022","unstructured":"Bankole AA, Nwaonu JN. The shifting landscape of lupus nephritis management: a review. Cureus. 2022, 14:e20950. 10.7759\/cureus.20950","journal-title":"Cureus"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001578","article-title":"Total tubulointerstitial score: a simple and effective predictor of long-term mortality and adverse renal outcomes in lupus nephritis","volume":"12","author":"Zhang X","year":"2025","unstructured":"Zhang X, Zhang M, Shi X, et al.. Total tubulointerstitial score: a simple and effective predictor of long-term mortality and adverse renal outcomes in lupus nephritis. Lupus Sci Med. 2025, 12:0. 10.1136\/lupus-2025-001578","journal-title":"Lupus Sci Med"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.2188\/jea.15.146","article-title":"Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980-1999","volume":"15","author":"Tanihara S","year":"2005","unstructured":"Tanihara S, Hayakawa T, Oki I, et al.. Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980-1999. J Epidemiol. 2005, 15:146-53. 10.2188\/jea.15.146","journal-title":"J Epidemiol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1159\/000545382","article-title":"Kidney outcomes with corticosteroid treatment in IgA nephropathy according to the Oxford-MEST-C classification","volume":"5","author":"Satirapoj B","year":"2025","unstructured":"Satirapoj B, Chueaboonchai T, Nata N, Supasyndh O. Kidney outcomes with corticosteroid treatment in IgA nephropathy according to the Oxford-MEST-C classification. Glomerular Dis. 2025, 5:191-9. 10.1159\/000545382","journal-title":"Glomerular Dis"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery","volume":"38","author":"Mastellos DC","year":"2017","unstructured":"Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery. Trends Immunol. 2017, 38:383-94. 10.1016\/j.it.2017.03.003","journal-title":"Trends Immunol"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-015-0227-8","article-title":"Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression","volume":"29","author":"Chakera A","year":"2016","unstructured":"Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts IS. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol. 2016, 29:367-75. 10.1007\/s40620-015-0227-8","journal-title":"J Nephrol"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002008","article-title":"Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation","volume":"102","author":"Alasfar S","year":"2018","unstructured":"Alasfar S, Matar D, Montgomery RA, et al.. Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation. Transplantation. 2018, 102:e115-20. 10.1097\/TP.0000000000002008","journal-title":"Transplantation"},{"key":"ref144","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2023.09.001","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","author":"Rovin BH","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM, Liu Z-H, Mej\u00eda-Vilet JM, Floege J. KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Kidney Int. 2024, 105:S1-69.","journal-title":"Kidney Int"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema IM","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, et al.. Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018, 93:789-96. 10.1016\/j.kint.2017.11.023","journal-title":"Kidney Int"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy005","article-title":"Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy","volume":"12","author":"Rodas LM","year":"2019","unstructured":"Rodas LM, Matas-Garc\u00eda A, Barros X, et al.. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J. 2019, 12:36-41. 10.1093\/ckj\/sfy005","journal-title":"Clin Kidney J"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2022.2114368","article-title":"What is the prognosis of ANCA-associated glomerulonephritis with immune deposition?","volume":"44","author":"Xiao X","year":"2022","unstructured":"Xiao X, Ren H, Gao P, et al.. What is the prognosis of ANCA-associated glomerulonephritis with immune deposition?. Ren Fail. 2022, 44:1477-85. 10.1080\/0886022X.2022.2114368","journal-title":"Ren Fail"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2024.e00446","article-title":"Liquid biopsy in cancer management: integrating diagnostics and clinical applications","volume":"43","author":"Pandey S","year":"2025","unstructured":"Pandey S, Yadav P. Liquid biopsy in cancer management: integrating diagnostics and clinical applications. Pract Lab Med. 2025, 43:e00446. 10.1016\/j.plabm.2024.e00446","journal-title":"Pract Lab Med"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.03.010","article-title":"Atypical anti-glomerular basement membrane disease","volume":"8","author":"Bharati J","year":"2023","unstructured":"Bharati J, Yang Y, Sharma P, Jhaveri KD. Atypical anti-glomerular basement membrane disease. Kidney Int Rep. 2023, 8:1151-61. 10.1016\/j.ekir.2023.03.010","journal-title":"Kidney Int Rep"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1159\/000543863","article-title":"Updates on glomerular diseases: a summary of inaugural GlomCon Hawaii 2024","volume":"5","author":"Ebrahimi N","year":"2025","unstructured":"Ebrahimi N, Mehr AP, Seethapathy H, et al.. Updates on glomerular diseases: a summary of inaugural GlomCon Hawaii 2024. Glomerular Dis. 2025, 5:158-67. 10.1159\/000543863","journal-title":"Glomerular Dis"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05480421","article-title":"Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study","volume":"16","author":"Bobart SA","year":"2021","unstructured":"Bobart SA, Han H, Tehranian S, et al.. Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study. Clin J Am Soc Nephrol. 2021, 16:1833-9. 10.2215\/CJN.05480421","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000697","article-title":"Membranous nephropathy: current understanding of various causes in light of new target antigens","volume":"30","author":"Ronco P","year":"2021","unstructured":"Ronco P, Debiec H. Membranous nephropathy: current understanding of various causes in light of new target antigens. Curr Opin Nephrol Hypertens. 2021, 30:287-93. 10.1097\/MNH.0000000000000697","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3838-6","article-title":"Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how?","volume":"34","author":"Preston R","year":"2019","unstructured":"Preston R, Stuart HM, Lennon R. Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how?. Pediatr Nephrol. 2019, 34:195-210. 10.1007\/s00467-017-3838-6","journal-title":"Pediatr Nephrol"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15161219","article-title":"APOL1 nephropathy: from genetics to clinical applications","volume":"16","author":"Friedman DJ","year":"2021","unstructured":"Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol. 2021, 16:294-303. 10.2215\/CJN.15161219","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093263","article-title":"Modern biomarkers in IgA nephropathy and their potential in paediatric research","volume":"14","author":"Such-Gruchot A","year":"2025","unstructured":"Such-Gruchot A, Mizerska-Wasiak M, P\u0142atos E, Pa\u0144czyk-Tomaszewska M. Modern biomarkers in IgA nephropathy and their potential in paediatric research. J Clin Med. 2025, 14:3263. 10.3390\/jcm14093263","journal-title":"J Clin Med"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.11.005","article-title":"Systematic review of the link between Oxford MEST-C classification and complement activation in IgA nephropathy","volume":"9","author":"\u0218tefan G","year":"2024","unstructured":"\u0218tefan G, Alamartine E, Mariat C, Maillard N. Systematic review of the link between Oxford MEST-C classification and complement activation in IgA nephropathy. Kidney Int Rep. 2024, 9:356-69. 10.1016\/j.ekir.2023.11.005","journal-title":"Kidney Int Rep"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2024.100408","article-title":"Advancements in pathology: digital transformation, precision medicine, and beyond","volume":"16","author":"Ahuja S","year":"2025","unstructured":"Ahuja S, Zaheer S. Advancements in pathology: digital transformation, precision medicine, and beyond. J Pathol Inform. 2025, 16:100408. 10.1016\/j.jpi.2024.100408","journal-title":"J Pathol Inform"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.037","article-title":"Glomerular classification using convolutional neural networks based on defined annotation criteria and concordance evaluation among clinicians","volume":"6","author":"Yamaguchi R","year":"2021","unstructured":"Yamaguchi R, Kawazoe Y, Shimamoto K, et al.. Glomerular classification using convolutional neural networks based on defined annotation criteria and concordance evaluation among clinicians. Kidney Int Rep. 2021, 6:716-26. 10.1016\/j.ekir.2020.11.037","journal-title":"Kidney Int Rep"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1159\/000515199","article-title":"IgA nephropathy: \"The times they are a-changin\"","volume":"2","author":"Glassock RJ","year":"2022","unstructured":"Glassock RJ. IgA nephropathy: \"The times they are a-changin\". Glomerular Dis. 2022, 2:4-14. 10.1159\/000515199","journal-title":"Glomerular Dis"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S341842","article-title":"Evaluating avacopan in the treatment of ANCA-associated vasculitis: design, development and positioning of therapy","volume":"19","author":"van Leeuwen JR","year":"2025","unstructured":"van Leeuwen JR, Quartuccio L, Draibe JB, Gunnarson I, Sprangers B, Teng YK. Evaluating avacopan in the treatment of ANCA-associated vasculitis: design, development and positioning of therapy. Drug Des Devel Ther. 2025, 19:23-37. 10.2147\/DDDT.S341842","journal-title":"Drug Des Devel Ther"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020584","article-title":"New treatment regimens, new drugs, and new treatment goals for lupus nephritis","volume":"14","author":"Rossi GM","year":"2025","unstructured":"Rossi GM, Vaglio A. New treatment regimens, new drugs, and new treatment goals for lupus nephritis. J Clin Med. 2025, 14:584. 10.3390\/jcm14020584","journal-title":"J Clin Med"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1159\/000529605","article-title":"Long-term safety, clinical and immunological outcomes in primary membranous nephropathy with severe renal impairment treated with cyclophosphamide and steroid-based regimen","volume":"3","author":"Ragy O","year":"2023","unstructured":"Ragy O, Hamilton P, Pathi A, Ahmed AA, Mitra S, Kanigicherla DA. Long-term safety, clinical and immunological outcomes in primary membranous nephropathy with severe renal impairment treated with cyclophosphamide and steroid-based regimen. Glomerular Dis. 2023, 3:88-97. 10.1159\/000529605","journal-title":"Glomerular Dis"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00280121","article-title":"Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas","volume":"16","author":"Uffing A","year":"2021","unstructured":"Uffing A, Hullekes F, Riella LV, Hogan JJ. Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas. Clin J Am Soc Nephrol. 2021, 16:1730-42. 10.2215\/CJN.00280121","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla D","year":"2013","unstructured":"Kanigicherla D, Gummadova J, McKenzie EA, et al.. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013, 83:940-8. 10.1038\/ki.2012.486","journal-title":"Kidney Int"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.09.007","article-title":"Transcriptomics and solid tumors: the next frontier in precision cancer medicine","volume":"84","author":"Tsimberidou AM","year":"2022","unstructured":"Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. Transcriptomics and solid tumors: the next frontier in precision cancer medicine. Semin Cancer Biol. 2022, 84:50-9. 10.1016\/j.semcancer.2020.09.007","journal-title":"Semin Cancer Biol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406637-patterns-of-glomerular-injury-histopathological-classification-and-clinical-correlation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:14:14Z","timestamp":1757171654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406637-patterns-of-glomerular-injury-histopathological-classification-and-clinical-correlation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":165,"URL":"https:\/\/doi.org\/10.7759\/cureus.91728","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,6]]}}}